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Background: Smokeless tobacco is consumed in most countries in the world. In view of its widespread use and
increasing awareness of the associated risks, there is a need for a detailed assessment of its impact on health. We
present the first global estimates of the burden of disease due to consumption of smokeless tobacco by adults.
Methods: The burden attributable to smokeless tobacco use in adults was estimated as a proportion of the
disability-adjusted life-years (DALYs) lost and deaths reported in the 2010 Global Burden of Disease study. We used
the comparative risk assessment method, which evaluates changes in population health that result from modifying
a population’s exposure to a risk factor. Population exposure was extrapolated from country-specific prevalence of
smokeless tobacco consumption, and changes in population health were estimated using disease-specific risk
estimates (relative risks/odds ratios) associated with it. Country-specific prevalence estimates were obtained through
systematically searching for all relevant studies. Disease-specific risks were estimated by conducting systematic
reviews and meta-analyses based on epidemiological studies.
Results: We found adult smokeless tobacco consumption figures for 115 countries and estimated burden of disease
figures for 113 of these countries. Our estimates indicate that in 2010, smokeless tobacco use led to 1.7 million
DALYs lost and 62,283 deaths due to cancers of mouth, pharynx and oesophagus and, based on data from the
benchmark 52 country INTERHEART study, 4.7 million DALYs lost and 204,309 deaths from ischaemic heart disease.
Over 85 % of this burden was in South-East Asia.
Conclusions: Smokeless tobacco results in considerable, potentially preventable, global morbidity and mortality from
cancer; estimates in relation to ischaemic heart disease need to be interpreted with more caution, but nonetheless
suggest that the likely burden of disease is also substantial. The World Health Organization needs to consider
incorporating regulation of smokeless tobacco into its Framework Convention for Tobacco Control.Background
Smokeless tobacco (SLT) consists of a number of prod-
ucts containing tobacco, which are consumed—without
burning—through the mouth or nose [1]. A diverse
range of SLT products are available worldwide, varying
in their composition, methods of preparation and con-
sumption, and associated health risks (Table 1) [1]. Its
use is most prevalent in South and South-East Asia
where one-third of tobacco is consumed in smokeless* Correspondence: Kamran.siddiqi@york.ac.uk
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article, unless otherwise stated.form [2, 3]. Wrapped in a betel leaf with areca nut,
slaked lime, and catechu, SLT is often served at social
occasions in this region. Other products (e.g. gutkha,
khaini) contain slaked lime, areca nut, flavourings, and
aromatic substances [4]. A number of products based on
powdered tobacco (e.g. snus) are also consumed in Nordic
countries and North America. In other parts of world, the
most commonly used SLT products (Table 1) include
Chimó (Venezuela), Nass (Uzbekistan, Kyrgyzstan),
Tambook (Sudan, Chad), and Snuff (Nigeria, Ghana,
South Africa).
In addition to nicotine, SLT products contain over 30
carcinogens [5] including tobacco-specific nitrosaminesle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Smokeless tobacco products consumed most commonly across the world
Smokeless tobacco
products
Regions (WHO) Countries (highest consumption) Other ingredients Preparation and use pHa Nicotinea (mg/g) Total TSNAa (ng/g)
Snus (Swedish) Europe (Region A) Nordic countries (Denmark,
Finland, Iceland, Norway,
Sweden)
Water, sodium carbonate,
sodium chloride, moisturisers,
flavouring
A heat treatment process;
placed between the gum
and upper lip
6.6–7.2 7.8–15.2 601–723
Plug, Snuff (US),
Snus (US)
Americas (Region A and B) US, Canada, Mexico Sweeteners, liquorice Plug; air cured 4.7–7.8 3.9–40.1 313–76,500
Dry or moist snuff; finely
ground and fire cured
Snus; steam cured
Snuff; kept between lip and
gum, dry snuff can be
inhaled too
Chimó Americas (Region B) Venezuela, Colombia Sodium bicarbonate, brown
sugar, Mamo’n tree ashes
Tobacco paste made from
tobacco leaves; placed between
the lip or cheek and gum and
left there for some time
6.9–9.4 5.3–30.1 9390
Nass (Naswar) Europe (Region B) and Eastern
Mediterranean (Region D)
Uzbekistan, Kyrgyzstan, Tajikistan,
Afghanistan, Pakistan, Iran
Lime, ash, flavourings
(cardamom), indigo
Sundried and powdered; placed
between lip or cheek and gum
8.4–9.1 8.9–14.2 478–1380
Tambook Eastern Mediterranean (Region D)
and Africa (Region D)
Sudan, Chad Mixed with moist sodium
bicarbonate
Fermented and grounded;
placed and kept in mouth
7.3–10.1 9.6–28.2 302,000–992,000
Snuff (North and
West African)
Africa (Region D) Nigeria, Ghana, Algeria,
Cameroon, Chad, Senegal
Dried tobacco leaves mixed
with potassium nitrate and
other salts
Dry snuff; finely ground and
inhaled as a pinch
9.0–9.4 2.5–7.4 1520–2420
Moist snuff is placed in mouth
Snuff (South African) Africa (Region E) South Africa Dried tobacco leaves mixed
with ash
Dry snuff; finely ground and
inhaled as a pinch
6.5–10.1 1.2–17.2 1710–20,500
Khaini South East Asia (Regions B and D)
Western Pacific (Region B)
Eastern Mediterranean (Region D)
Europe (Region A)
India, Bangladesh, Nepal, Bhutan Slaked lime, menthol,
flavourings, areca nut
Shredded; kept in mouth
between lips and gum
9.6–9.8 2.5–4.8 21,600–23,900
Zarda Bangladesh, India, Pakistan,
Myanmar, Thailand, Indonesia,
Nepal, Maldives, Sri Lanka, UK
Served wrapped in a betel
leaf with lime, catechu,
areca nuts
Shredded tobacco leaves are
boiled with lime and saffron;
the mixture is dried then
chewed and spat
5.2–6.5 9.5–30.4 5490–53,700
Gutkha India, Pakistan, Bangladesh,
Nepal, Myanmar, Sri Lanka, UK
Betel nut, catechu, flavourings,
sweeteners
Commercially manufactured;
sucked, chewed, and spat
7.4–8.9 0.2–4.2 83–23,900
WHO World Health Organization, TSNA tobacco-specific nitrosamines
aFigures are adapted from Stanfill et al. [6], Lawler et al. [17], and NIH & CDC 2014 report on smokeless tobacco products [37]
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Siddiqi et al. BMC Medicine  (2015) 13:194 Page 3 of 22(TSNA), arsenic, beryllium, cadmium, nickel, chromium,
nitrite, and nitrate. The level of nicotine and carcinogens
vary between products (Table 1) [6]. For example, nico-
tine content among SLT products varies between 0.2
and 40.1 mg/g, compared to commercial filtered ciga-
rettes which contain 16.3 mg/g of nicotine [7]. Their pH
also varies, which, being a key determinant of the level
of absorption of nicotine and carcinogens, determines its
toxicity: the higher the pH, the higher the absorption
and, consequently, the higher the toxicity [6]. Such con-
siderations mean that there are substantial variations be-
tween different SLT products in the level of risk posed
to human health [4, 8–11]. It is therefore important not
to consider SLT as a single product, but rather as groups
of products with differences in their toxicity and addic-
tiveness depending upon their carcinogen, nicotine, and
pH levels. The diversity in SLT toxicity has been an
impediment not only in establishing its global risks to
human health, but also in agreeing on international pol-
icies for its prevention and control. It is therefore per-
haps unsurprising that despite several country-specific
studies [12–15] no attempt has hitherto been made to
estimate its global disease burden.
To overcome these challenges, we developed a novel
approach to estimate the global burden associated with
the use of SLT products. The determinants of their tox-
icity (carcinogens and pH) and addictiveness (nicotine)
are dependent on preparation methods, ingredients that
are added to SLT products, and consumption behav-
iours. Given that the SLT preparations and consumption
patterns are determined by, and vary with, geography
and culture [16], it is possible to group them according
to their availability in different parts of the world
(Table 1). These groups of SLT products, classified ac-
cording to different geographical regions, will also be
distinguishable from each other on the basis of their tox-
icity, addictiveness, and associated health risks. Hence,
the risks were assumed to be highest in those regions and
cultures where products are combined with other ingredi-
ents, and are prepared and consumed in a way that makes
them very alkaline (i.e. a high pH), and rich in nicotine and
TSNA [6, 17]. Building on this assumption, we aimed to
estimate the worldwide burden of disease attributable to
SLT use, measured in terms of disability adjusted life years
(DALYs) lost and number of deaths in 2010.
Methods
We used the comparative risk assessment method,
which evaluates changes in population health (burden of
disease) that result from modifying a population’s expos-
ure to a risk factor [18, 19]. For this, we used 2010 data-
sets, which provided the most recent global estimates of
burden of disease [20]. The estimates were calculated for
individual countries and then grouped into 14 WorldHealth Organization (WHO) sub-regions (Additional
file 1: Appendix 1) [21]. These were generated through
estimating the following:
1. The prevalence of SLT consumption
2. Diseases caused by SLT use
3. The relative risks of acquiring these diseases
4. The population attributable fraction (PAF) for each
of these diseases
5. The overall burden of these diseases in terms of
DALYs lost and deaths
6. Proportion of this burden attributable to SLT use
Prevalence of smokeless tobacco use
We carried out a systematic literature search (see
Additional file 1: Appendix 2 for a detailed description of
the methods employed) for the point prevalence (current
use) of SLT consumption among all adult (≥15 years) pop-
ulations, and also for men and women separately. Only
one prevalence report was included for one country. Latest
national prevalence data collected as part of an inter-
national or regional survey were preferred over an older
isolated national or a sub-national survey. We used data
from the Global Adult Tobacco Survey (GATS), where
available [22]. In its absence, other international (WHO
STEPwise approach to Surveillance, The Demographic and
Health Surveys), regional (Special Europe Barometer), na-
tional, and/or sub-national surveys were used to extract
prevalence data.
Diseases caused by smokeless tobacco use
A scoping review was carried out to identify associated
diseases. A series of focused literature reviews were sub-
sequently carried out to find and assess the evidence of
causation between each of these diseases and SLT use.
Our search strategies and selection criteria are provided
in Additional file 1: Appendix 3. One researcher ran the
searches, which were then independently scrutinised by
another independent researcher who considered the
search results against the pre-specified inclusion and ex-
clusion criteria. Similarly, one researcher extracted data,
which were independently crosschecked by another re-
searcher. In particular, we appraised the studies for case
definitions for diseases and for assessment methods for
measuring exposure to SLT and for investigating the ef-
fects of potential confounders. We excluded those dis-
eases (and respective studies) where evidence was not
supportive of a causal relationship. Only studies that ad-
equately controlled for smoking and/or alcohol as poten-
tial confounders either at the design or the analysis stage
were carried forward into the next stage of the analysis
(discussed below). Quality was assessed using the
Newcastle-Ottawa Scale for assessing the quality of non-
randomised studies in meta-analyses [23].
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Risk estimates (relative risks/odds ratios) and their confi-
dence intervals (CI) were log transformed to produce ef-
fect sizes and standard errors, respectively [24]. We
carried out random effects meta-analysis using RevMan
version 5 to estimate pooled risk estimates. We first ob-
tained country-specific risk estimates (relative risks/odds
ratios) for individual diseases by pooling data from the
included studies carried out in respective countries. We
then extrapolated non-specific global risk estimates by
pooling respective country-specific risk estimates. We
were mindful that the risk of acquiring diseases varies
between countries owing to differences in SLT products
used. Therefore, for each disease where good country-
specific risk estimates (pooled estimate from a meta-
analysis of three or more studies in respective country)
were available, we applied these to respective countries
and also to those countries and regions where similar
SLT products are used. In the absence of good country-
specific risk estimates, we used either one of the follow-
ing two approaches: (a) In countries and regions that
use SLT products with moderate to high pH and TSNAs
levels, we applied non-specific global estimates (pooled
estimate from a meta-analysis of all studies); and (b) in
countries and regions where there was either no infor-
mation available on the SLT products or the information
available indicates low levels of pH and TSNA, we did
not apply any estimates. Further details on the applica-
tion of these assumptions across all 14 WHO regions
are provided in web Additional file 1: Appendix 4. We
only used those pooled relative risks (country or non-
specific) that were found to be statistically significant.
Where associations were presented for more than one
SLT product in the same paper, we considered these as
separate studies for the purpose of meta-analysis. Similarly,
where risks were given separately for former and current
SLT users, these were also treated as separate studies. We
did not attempt to group risks according to gender because
very few studies had such sub-group analysis.
Population attributable fraction
PAF is the proportional reduction in disease or mortality
that would occur if exposure were reduced to zero [25, 26].
PAF was estimated for each disease for each country for
both males and females, using the following formula:
PAF ¼ Pe RRe–1ð Þ= 1þ Pe RRe–1ð Þ½ 
Pe ¼ Prevalence
RRe ¼ Relative Risk
Overall burden
The overall number of DALYs and deaths for each asso-
ciated disease for both males and females for eachcountry were extracted from the 2010 Global Burden of
Disease study [27, 28].
Attributable burden
The attributable burden (AB), in deaths and DALYs, was
estimated for each associated disease for each country
for both males and females by multiplying PAF by the
overall burden of the disease (B):
AB ¼ PAF B
Results
Prevalence of smokeless tobacco use
We found adult prevalence figures for SLT consumption
in 115 countries (Fig. 1). The definition for ‘adult’ ranged
from 15, 16, 25, or 35 years at one end to 49, 64, 65, 70,
74, 84, 85, 89, or no age limit at the other. The PRISMA
diagram describing the selection of the prevalence re-
ports is provided in Additional file 1: Appendix 5a.
In general, SLT consumption was higher among males
than females (Table 2). Mauritania had the highest
prevalence of SLT consumption among females (28.3 %),
followed by Bangladesh (27.9 %), Madagascar (19.6 %),
India (18.4 %), and Bhutan (17.3 %). Among males,
Myanmar (51.4 %), Nepal (37.9 %), India (32.9 %),
Uzbekistan (31.8 %), and Bangladesh (26.4 %) had the
highest consumption rates. Within Europe, SLT (snus)
consumption was high in Sweden (24.0 % males, 7.0 %
females) and Norway (20.0 % males, 6.0 % females).
Diseases caused by smokeless tobacco use
The initial scoping review identified a number of associ-
ated diseases, including a range of cancers, cardiovas-
cular diseases (ischaemic heart disease and stroke),
periodontal conditions, and adverse pregnancy outcomes.
The subsequent more focused systematic reviews identi-
fied 53 studies (Table 3) reporting association between
SLT consumption and cancers of mouth, pharynx, larynx,
oesophagus, lung, and pancreas (39 studies); and cardio-
vascular diseases, such as ischaemic heart disease and
stroke (14 studies). PRISMA flow diagrams describing
the selection process of the studies identified in the
literature searches are provided in Additional file 1:
Appendix 5b,c. The pooled non-specific relative risks
were statistically significant for cancers of the mouth,
pharynx, and oesophagus (Figs. 2, 3, 4, and 5). Only
statistically significant relative risks (country-specific
or non-specific) were included in the model to esti-
mate attributable risks. For example, the pooled non-
specific relative risk for laryngeal cancer was 1.42 (95 % CI
0.77–2.59), and hence excluded (Additional file 1:
Appendix 6). Likewise, none of the country-specific
estimates for the USA were statistically significant
Fig. 1 Smokeless tobacco prevalence among males and females
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Table 2 Prevalence of smokeless tobacco use in different countries of the world according to WHO sub-regional classification
WHO sub-regions Country M F Source Year
Africa (Region D) Algeria 21 0.4 STEPS [38] 2005
Benin 12.7 5.7 STEPS [38] 2008
Burkina Faso – 3.86 DHS [39] 2011
Cameroon 1.94 0.94 DHS [39] 2011
Cape Verde 3.5 5.8 STEPS [38] 2007
Chad 1.9 0.4 STEPS [38] 2008
Comoros 7.72 2.99 DHS [39] 2012
Gabon 0.48 0.34 DHS [39] 2012
Gambia 0.8 1.4 STEPS [38] 2010
Ghana 1.33 0.2 DHS [39] 2008
Guinea 1.4 1.5 STEPS [38] 2009
Liberia 2.3 2.4 DHS [40] 2007
Madagascar 24.66 19.6 DHS [39] 2009
Mali 5 1.2 STEPS [38] 2007
Mauritania 5.7 28.3 STEPS [38] 2006
Niger 4.55 2.3 DHS [39] 2012
Nigeria 3.2 0.5 DHS [40] 2008
Sao Tome & Principe 3.8 1.9 STEPS [38] 2009
Senegal 6.63 0.23 DHS [39] 2011
Sierra Leone 3 12 STEPS [38] 2009
Togo 5.1 2.2 STEPS [38] 2010
Africa (Region E) Botswana 7.2 14.5 STEPS [38] 2007
Burundi 0.03 0.31 DHS [39] 2011
Congo (Brazzaville) 8.3 1.54 DHS [39] 2012
Congo (Republic) 8.67 3.22 DHS [39] 2013
Cote d'Ivoire 0.61 1.27 DHS [39] 2012
Eritrea 5.8 0.2 STEPS [38] 2004
Ethiopia 1.94 0.2 DHS [39] 2011
Kenya 2.05 1.29 DHS [39] 2008
Lesotho 1.3 9.1 DHS [40] 2009
Malawi 1.9 5 STEPS [38] 2009
Mozambique 10.94 0.82 DHS [39] 2011
Namibia 1.8 2.3 DHS [40] 2006–07
Rwanda 5.8 2.73 DHS [39] 2011
South Africa 2.4 10.9 DHS [41] 2003
Swaziland 2.6 0.8 STEPS [38] 2007
Tanzania 2.03 0.83 DHS [39] 2010
Uganda 2.94 1.5 DHS [39] 2011
Zambia 0.3 1.2 DHS [39] 2007
Zimbabwe 1.6 0.4 DHS [41] 2011
Americas (Region A) Canada 2 – ICS [41] 2011
USA 6.5 0.4 ICS [41] 2010
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Table 2 Prevalence of smokeless tobacco use in different countries of the world according to WHO sub-regional classification
(Continued)
Americas (Region B) Argentina 0.1 0.2 GATS [42] 2012
Barbados 0 0.6 STEPS [38] 2007
Brazil 0.6 0.3 GATS [42] 2010
Dominican Republic 1.9 0.3 DHS [40] 2007
Grenada 2.2 0.3 STEPS [38] 2011
Mexico 0.3 0.3 GATS [42] 2009
Paraguay 3 1.6 ICS [41] 2011
St Kitts & Nevisa 0.3 0.1 STEPS [38] 2007
Trinidad & Tobago 0.5 0.3 STEPS [38] 2011
Venezuela 6.2 0.9 ICS [41] 2011
Americas (Region D) Haiti – 2.5 DHS [40] 2005–06
Eastern Mediterranean (Region B) Libya 2.2 0.1 STEPS [38] 2009
Saudi Arabia 1.3 0.5 STEPS [38] 2004
Tunisia 8.6 2.2 ICS [41] 2005–06
Eastern Mediterranean (Region D) Egypt 4.8 0.3 GATS [42] 2009
Iraq 1.6 0.3 STEPS [38] 2006
Pakistan 16.3 2.44 DHS [43] 2012–13
Sudan 24.1 1 STEPS [38] 2005
Yemen 15.1 6.2 ICS [41] 2003
Europe (Region A) Austria 7.8 1.1 SEBS [44] 2012
Belgium 1.1 0.6 SEBS [44] 2012
Cyprus 2.1 0.4 SEBS [44] 2012
Czech Republic 2.5 0.4 SEBS [44] 2012
Denmark 3 1 ICS [41] 2010
Finland 5.5 0.3 ICS [41] 2011
France 1.2 0.6 SEBS [44] 2012
Germany 3.4 3.4 SEBS [44] 2012
Iceland 5.97 – ICS [41] 2008
Ireland 2.2 0.9 SEBS [44] 2012
Italy 1.8 1.5 SEBS [44] 2012
Luxembourg 1.8 1 SEBS [44] 2012
Malta 5.5 1.5 SEBS [44] 2012
Netherlands 0.3 0.1 ICS [41] 2011
Norway 20 6 ICS [41] 2011
Portugal 4.4 1.1 SEBS [44] 2012
Slovenia 1.8 0.4 SEBS [44] 2012
Spain 0.4 0.2 SEBS [44] 2012
Sweden 24 7 ICS [41] 2011
Switzerland 4 1.3 ICS [41] 2011
United Kingdom 1.6 0.5 SEBS [44] 2012
Europe (Region B) Ajerbaijan 0.3 0 DHS [40] 2006
Armenia 1.8 0 DHS [40] 2005
Bulgaria 0.3 0 SEBS [44] 2012
Georgia 1 0.2 ICS [41] 2010
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Table 2 Prevalence of smokeless tobacco use in different countries of the world according to WHO sub-regional classification
(Continued)
Kyrgyzstan 7 0.3 ICS [41] 2006
Poland 1 0.1 GATS [42] 2009
Romania 0.4 0.2 GATS [42] 2011
Slovakia 3.9 0.7 SEBS [44] 2012
Uzbekistan 31.8 0.2 DHS [40] 2002
Europe (Region C) Latvia 5.8 0.9 ICS [41] 2010
Lithuania 1.2 0.2 SEBS [44] 2012
Moldova 0.1 0 DHS [40] 2005
Russia 1 0.2 GATS [42] 2009
Ukraine 0.5 0 GATS [42] 2010
South East Asia (Region B) Indonesia 1.5 2 GATS [42] 2011
Sri Lanka 24.9 6.9 STEPS [38] 2006
Thailand 1.1 5.2 GATS [42] 2011
South East Asia (Region D) Bangladesh 26.4 27.9 GATS [42] 2009
Bhutan 21.1 17.3 STEPS [38] 2007
India 32.9 18.4 GATS [42] 2009
Maldives 5.6 2.6 STEPS [38] 2011
Myanmar 51.4 16.1 STEPS [38] 2009
Nepal 37.9 6 DHS [41] 2011
Timor Leste 2.48 1.93 DHS [43] 2009–10
Western Pacific (Region A) Australia 0.75 0.41 ICS [45] 2004
Western Pacific (Region B) Cambodia 2.2 14.8 STEPS [38] 2010
China 0.7 0 GATS [42] 2010
Lao People’s Democratic Republic 14.6 1.1 STEPS [38] 2008
Malaysia 0.9 0.6 GATS [42] 2011
Micronesia 22.4 3 STEPS [38] 2002
Mongolia 2.8 0.5 STEPS [38] 2009
Philippines 2.8 1.2 GATS [42] 2009
Vietnam 0.3 2.3 GATS [42] 2010
DHS The Demographic and Health Surveys, ICS Individual Country Survey, GATS Global Adult Tobacco Survey, SEBS The Special Europe Barometer Survey,
STEPS STEPwise approach to Surveillance
aPopulations of St Kitts and Nevis are tiny and unlikely to affect our estimates
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reviews, we assumed that a causal association exists be-
tween some SLT products and cancers of the mouth,
pharynx, and oesophagus, and ischaemic heart disease.
Relative risks
Based on 32 studies, the estimated pooled non-specific
relative risk for mouth (oral cavity, tongue, and lip) can-
cers was 3.43 (95 % CI 2.26–5.19) (Fig. 2). Studies from
South-East Asia indicated an increased risk of oral can-
cer for SLT use whereas results from studies pertaining
to Europe and the Americas did not substantiate such
an association. For cancers of the pharynx, pooled non-
specific relative risk was 2.23 (95 % CI 1.55–3.20), basedon ten studies (Fig. 3). For oesophageal cancers, no clear
increased risk was present in studies in the USA,
whereas a pooled estimate reported a relative risk of
2.17 (95 % CI 1.70–2.78) (Fig. 4). For ischaemic heart
disease, no good country-specific risk estimates were
available (Fig. 5). However, we found one large case–
control study (INTERHEART study) [29] conducted in
52 countries from all regions showing a statistically sig-
nificant risk of ischaemic heart disease (adjusted odds
ratio 1.57, 95 % CI 1.24–1.99) among SLT users.
Applying risk estimates
For cancers in general, pooled country-specific risk esti-
mates obtained from Sweden and the USA were applied
Table 3 Smokeless tobacco use and risk of cancers, ischaemic heart disease, and stroke—studies included in meta-analysis
Country Study period Study design Exposure status Inclusion of
cigarette/alcohol
users
Outcome Odds ratios/relative risks
(95 % confidence intervals)
Comments Quality assessment
(NOS)a
Reference
CANCERS
India 2001–2004 Case–control Smokeless tobacco
with or without
additives
No/No Oral cancer 0.49 (0.32–0.75) Exclusive SLT users Selection**** Anantharaman
et al. 2007 [46]
Comparability**
Exposure/Outcome*
India 1996–1999 Case–control Ever SLT users Yes/Yes Oral cancer 7.31 (3.79–14.1) Never drinkers
adjusted for
smoking
Selection**** Balaram et al.
2002 [47]
9.19 (4.38–19.28) Never smokers
adjusted for
alcohol
Comparability**
Exposure/Outcome *
India 1982–1992 Case–control Tobacco quid
chewing
Yes/No Oral cancer 5.8 (3.6–9.34) Adjusted for
smoking
Selection*** Dikshit & Kanhere
2000 [48]
Pharyngeal cancer 1.2 (0.8–1.8) Comparability*
Lung cancer 0.7 (0.4–1.22) Exposure/Outcome*
India Unclear Case–control Chewing tobacco No/No Oral cancer 10.75 (6.58–17.56) Exclusive SLT users Selection** Goud et al.
1990 [49]
Comparability*
Exposure/Outcome0
India 1990–1997 Cohort Current SLT users No/No Oral cancer 5.5 (3.3–9.17) Exclusive SLT users Selection**** Jayalekshmi et al.
2009 [50]
Former SLT users 9.2 (4.6–18.40) Comparability*
Exposure/Outcome**
India 1990–1997 Cohort Current SLT user Yes/Yes Oral cancer 2.4 (1.7–3.39) Adjusted for
smoking and
alcohol
Selection**** Jayalekshmi et al.
2010 [51]
Former SLT users 2.1 (1.3–3.39) Comparability*
Exposure/Outcome***
India May 2005 Case–control Ever SLT users No/No Oral cancer 4.23 (3.11–5.75) Exclusive SLT users Selection*** Jayant et al.
1977 [52]
Pharyngeal cancer 2.42 (1.74–3.37) Comparability**
Laryngeal cancer 2.8 (2.07–3.79) Exposure/Outcome0
Oesophageal cancer 1.55 (1.15–2.07)
India 1968 Case–control Tobacco Yes/No Oral cancer 4.63 (3.50–6.14) Exclusive chewers
and non-chewers
data available
Selection*** Jussawalla &
Deshpande 1971
[53]Pharyngeal cancer 3.09 (2.31–4.13) Comparability**
Laryngeal cancer 2.29 (1.72–3.05) Exposure/Outcome0
Oesophageal cancer 3.82 (2.84–5.13)
India 2005–2006 Case–control Tobacco flakes Yes/Yes Oral cancer 7.6 (4.9–11.79) Adjusted for
smoking and
alcohol
Selection**** Madani et al.
2010 [54]
Gutkha 12.7 (7–23.04) Comparability**
Mishiri 3.0 (1.9–4.74) Exposure/Outcome*
Siddiqiet
al.BM
C
M
edicine
 (2015) 13:194 
Page
9
of
22
Table 3 Smokeless tobacco use and risk of cancers, ischaemic heart disease, and stroke—studies included in meta-analysis (Continued)
India Unclear Case–control Chewing tobacco Yes/Yes Oral cancer 5.0 (3.6–6.94) Adjusted for
smoking and
alcohol
Selection**** Muwonge et al.
2008 [55]
Comparability*
Exposure/Outcome*
India 1982–1984 Case–control Chewing tobacco Yes/No Oral cancer 10.2 (2.6–40.02) Adjusted for
smoking
Selection*** Nandakumar
et al. 1990 [56]
Comparability**
Exposure/Outcome*
India 1980–1984 Case–control SLT users No/No Oral cancer 1.99 (1.41–2.81) Exclusive SLT users Selection** Rao et al.
1994 [57]
Comparability0
Exposure/Outcome*
India 1952–1954 Case–control Chewing tobacco No/No Oral cancer 4.85 (2.32–10.14) Exclusive SLT users Selection*** Sanghvi et al.
1955 [58]
Pharyngeal cancer 2.02 (0.94–4.33) Comparability**
Laryngeal cancer 0.76 (0.37–1.56) Exposure/Outcome0
India 1983–1984 Case–control Snuff (males only) Yes/Yes Oral cancer 2.93 (0.98–8.76) Adjusted for
smoking and
alcohol; adjusted
effect size is only
among males
Selection*** Sankaranarayan
et al. 1990 [59]
Comparability0
Exposure/Outcome*
India Not given Case–control Tobacco chewing Yes/Yes Oropharyngeal cancer 7.98 (4.11–13.58)b Adjusted for
smoking and
alcohol
Selection*** Wasnik et al.
1998 [60]
Comparability**
Exposure/Outcome0
India 1991–2003 Case–control Chewing tobacco No/No Oral cancer 5.88 (3.66–7.93) Exclusive SLT users Selection**** Subapriya e al.
2007 [61]
Comparability**
Exposure/Outcome**
India 1950–1962 Case–control Tobacco with or
without paan or
lime
Yes/No Oral and oropharyngeal
cancer
41.90 (34.20–51.33) Exclusive chewer
data available
Selection** Wahi et al.
1965 [62]
Note: data of habit
was not available
for the whole
cohort
Comparability**
Exposure/Outcome0
Pakistan 1996–1998 Case–control Naswar Yes/Yes Oral cancer 9.53 (1.73–52.50) Adjusted for
smoking and
alcohol
Selection*** Merchant et al.
2000 [63]
Paan with tobacco 8.42 (2.31–30.69) Comparability**
Exposure/Outcome*
Sweden 1973–2002 Cohort Snus Yes/Yes Oral and pharyngeal
combined
3.10 (1.50–6.41) Adjusted for
smoking and
alcohol
Selection** Roosar et al.
2008 [64]
Comparability**
Outcome***
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Table 3 Smokeless tobacco use and risk of cancers, ischaemic heart disease, and stroke—studies included in meta-analysis (Continued)
India 1993–1999 Case–control Chewing tobacco Yes/Yes Oral cancer 5.05 (4.26–5.99) Adjusted for
smoking and
alcohol
Selection*** Znaor et al.
2003 [65]
Pharynx 1.83 (1.43–2.34) Comparability**
Oesophagus 2.06 (1.62–2.62) Exposure/Outcome*
Norway 1966–2001 Cohort Chewing tobacco
plus oral snuff
No/No Oral cancer 1.1 (0.5–2.42) Adjusted for
smoking, might
be confounded
by alcohol use
Selection*** Bofetta et al.
2005 [66]
Oesophageal cancer 1.4 (0.61–3.21) Comparability*
Pancreatic cancer 1.67 (1.12–2.49) Exposure/Outcome***
Lung cancer 0.80 (0.61–1.05)
Sweden 1988–1991 Case–control Oral snuff Yes/Yes Oral cancer 1.4 (0.8–2.45) Adjusted for
smoking and
alcohol
Selection** Lewin et al.
1998 [67]
Larynx 0.9 (0.5–1.62) Comparability**
Oesophagus 1.2 (0.7–2.06) Exposure/Outcome*
Pharynx 0.7 (0.4–1.22)
Sweden 1969–1992 Cohort Snus No/No Oral cancer 0.8 (0.4–1.60) Exclusive SLT users Selection*** Luo et al.
2007 [68]
Lung cancer 0.8 (0.5–1.28) Comparability*
Pancreatic cancer 2 (1.20–3.33) Exposure/Outcome***
Sweden 2000–2004 Case–control Oral snuff Yes/Yes Oral 0.70 (0.3–1.63) Adjusted for
smoking and
alcohol
Selection*** Rosenquist et al
2005 [69]
Comparability**
Exposure/Outcome**
Sweden 1980–1989 Case–control Oral snuff Yes/Yes Oral cancer 0.8 (0.5–1.28) Adjusted for
smoking and
alcohol
Selection** Schildt et al.
1998 [70]
Comparability**
Exposure/Outcome***
USA 1972–1983 Case–control Oral snuff Yes/Yes Oral cancer 0.8 (0.4–1.60) Not clear if
adjusted for
smoking and
alcohol
Selection** Mashberg et al.
1993 [71]
Chewing tobacco 1 (0.7–1.43) Comparability0
Exposure/Outcome*
USA Not given Case–control SLT use Yes/Yes Oral cancer 0.90 (0.38–2.13) Adjusted for
smoking and
alcohol
Selection*** Zhou et al. 2013 [15]
Pharyngeal cancer 1.59 (0.84–3.01) Comparability**
Laryngeal cancer 0.67 (0.19–2.36) Exposure/Outcome*
India 2001–2004 Case–control Chewing tobacco No/No Pharyngeal cancer 3.18 (1.92–5.27) Exclusive SLT users Selection*** Sapkota et al.
2007 [72]
Laryngeal cancer 0.95 (0.52–1.74) Comparability**
Exposure/Outcome*
Pakistan 1998–2002 Case–control Snuff dipping No/No Oesophageal cancer 4.1 (1.3–12.93) Adjusted for
areca nut
Selection*** Akhtar et al.
2012 [73]
Quid with tobacco 14.2 (6.4–31.50) Comparability**
Exposure/Outcome**
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Table 3 Smokeless tobacco use and risk of cancers, ischaemic heart disease, and stroke—studies included in meta-analysis (Contin d)
India 2008–2012 Case–control Nass chewing No/No Oesophageal cancer 2.88 (2.06–4.03) Exclusive SLT ers Selection*** Dar et al.
2012 [74]
Gutkha chewing 2.87 (0.87–9.47) Comparability**
Exposure/Outcome**
India 2007–2011 Case–control Oral snuff Yes/Yes Oesophageal cancer 3.86 (2.46–6.06) Adjusted for
smoking and
alcohol
Selection** Sehgal et al.
2012 [75]
Comparability**
Exposure/Outcome*
India 2011–2012 Case–control Chewing tobacco Yes/Yes Oesophageal cancer 2.63 (1.53–4.52) Adjusted for
smoking and
alcohol
Selection*** Talukdar et al.
2013 [76]
Comparability**
Exposure/Outcome*
Sweden 1995–1997 Case–control Oral snuff Yes/Yes Oesophageal cancer
(adenocarcinoma)
1.2 (0.7–2.06) Adjusted for
smoking and
alcohol
Selection*** Lagergren et al.
2000 [77]
(Squamous cell
carcinoma)
1.4 (0.9–2.18) Comparability**
Exposure/Outcome*
Sweden 1969–1993 Cohort Oral snuff Yes/No Oesophageal cancer
(Adenocarcinoma)
1.3 (0.8–2.11) Adjusted for
smoking
Selection** Zendehdel et al.
2008 [78]
(Squamous cell
carcinoma)
1.2 (0.8–1.80) Comparability*
Exposure/Outcome**
Sweden 1974–1985 Cohort SLT users No/NA Lung cancer 0.90 (0.20– 4.05) Adjusted for e,
region of orig
Selection*** Bolinder et al.
1994 [79]
Comparability*
Outcome**
Morocco 1996–1998 Case–control SLT users Yes/No Lung cancer 1.05 (0.28–3.94) Adjusted for
smoking
Selection** Sasco et al.
2002 [80]
Comparability**
Exposure/Outcome**
USA 1977–1984 Case–control SLT users Yes/No Oesophageal cancer 1.2 (0.1–14.40) Adjusted for
smoking
Selection*** Brown et al.
1988 [81]
Comparability**
Exposure/Outcome**
USA 1986–1989 Case–control SLT users Yes/No Pancreatic cancer 1.4 (0.5–3.92) Adjusted for
smoking
Selection*** Alguacil &
Silverman 2004
[82]Comparability*
Exposure/Outcome**
USA 2000–2006 Case–control Chewing tobacco Yes/Yes Pancreatic cancer 0.6 (0.3–1.20) Adjusted for
smoking and
alcohol
Selection**** Hassan et al.
2007 [83]
Oral snuff 0.5 (0.1–2.5) Comparability**
Exposure/Outcome*
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Table 3 Smokeless tobacco use and risk of cancers, ischaemic heart disease, and stroke—studies included in meta-analysis (Continued)
CARDIOVASCULAR DISEASES (ischaemic heart disease and stroke)
52 countries 1999–2003 Case–control Chewing tobacco No/Yes Myocardial infarction 1.57 (1.24–1.99) Adjusted for
diabetes, abdominal
obesity, hypertension,
exercise, diet
Selection**** Teo et al.
2006 [29]
Comparability**
Exposure/Outcome*
Pakistan 2005–2011 Case–control Dippers only (Naswar) No/NA Myocardial infarction 1.46 (1.20–1.77) Adjusted for age, sex,
region, ethnicity
Selection**** Alexander 2013
[84]
Chewers only
(Paan/ Supari/ Gutkha)
1.71 (1.46–2.00) Comparability**
Exposure/Outcome**
Bangladesh 2006–2007 Case–control Ever SLT users No/NA Myocardial infarction,
Angina pectoris
2.8 (1.1–7.13) Adjusted for age,
sex, hypertension
Selection*** Rahman & Zaman
2008 [85]
Comparability**
Exposure/Outcome*
Bangladesh 2010 Case–control Ever SLT users No/NA Myocardial infarction,
Angina pectoris
0.77 (0.52–1.14) Adjusted for age,
hypertension,
diabetes, acute
psycho-social stress
Selection**** Rahman et al.
2012 [86]
Comparability**
Exposure/Outcome*
Sweden 1998–2005 Case–control Current SLT users No/NA Myocardial infarction 0.73 (0.35–1.52) Exclusive SLT users Selection*** Hergens et al.
2005 [87]
Former SLT users 1.2 (0.46–3.13) Comparability**
Exposure/Outcome**
Sweden 1978–2004 Cohort Ever SLT users No/NA Myocardial infarction 0.99 (0.90–1.10) Adjusted for age,
BMI, region of
residence
Selection** Hergens et al.
2007 [88]
Comparability**
Exposure/Outcome***
Sweden 1989–1991 Case–control Regular SLT users Yes/NA Myocardial infarction 1.01 (0.66–1.55)c Adjusted for age,
education, smoking
Selection*** Huhtasaari et al.
1992 [89]
Comparability**
Exposure/Outcome*
Sweden 1991–1993 Case–control Former SLT users No/NA Myocardial infarction 1.23 (0.54–2.82) Exclusive SLT users Selection**** Huhtasaari et al.
1999 [90]
Comparability**
Exposure/Outcome**
Sweden 1988–2000 Cohort Daily SLT users No/NA Ischaemic heart disease 1.41 (0.61–3.28) Adjusted for BMI,
physical activity,
diabetes,
hypertension
Selection**** Johansson et al.
2005 [91]
Comparability**
Exposure/Outcome**
Sweden 1985–1999 Case–control Current SLT users No/NA Myocardial infarction 0.82 (0.46–1.46) Adjusted for BMI,
physical activity,
education,
cholesterol
Selection**** Wennberg et al.
2007 [92]
Former SLT users 0.66 (0.32–1.36) Comparability**
Exposure/Outcome**
Sweden 1985–2000 Case–control Regular SLT users No/NA Stroke 0.87 (0.41–1.83) Adjusted for diabetes,
hypertension,
education, marital
status, cholesterol
Selection**** Asplund et al.
2003 [93]
Comparability**
Exposure/Outcome**
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Table 3 Smokeless tobacco use and risk of cancers, ischaemic heart disease, and stroke—studies included in meta-analysis (Continued)
Sweden 1978–2003 Cohort Ever SLT users No/NA Stroke 1.02 (0.92–1.13) Adjusted for age,
BMI, region of
residence
Selection** Hergens et al.
2008 [94]
Comparability**
Exposure/Outcome***
Sweden 1998–2005 Cohort Current SLT users No/NA Ischaemic heart disease 0.85 (0.51–1.42) Adjusted for age,
hypertension,
diabetes, cholesterol
Selection*** Hansson et al.
2009 [95]
Former SLT users Stroke 1.07 (0.56–2.04) Comparability**
1.18 (0.67–2.08) Exposure/Outcome**
1.35 (0.65–2.82)
Sweden 1991–2004 Cohort SLT users No/NA Myocardial infarction 0.75 (0.3–1.87) Adjusted for age,
diabetes, occupation,
hypertension, physical
activity, BMI, marital
status
Selection*** Janzon et al.
2009 [96]
Stroke 0.59 (0.2–1.5) Comparability**
Exposure/Outcome**
BMI body mass index, NA not applicable, NOS Newcastle-Ottawa Scale, SLT smokeless tobacco
aNOS for assessing the quality of non-randomised studies in meta-analyses based on selection, comparability, and exposure/outcome. Number of stars (*) indicates the number of criteria met for each of these three
categories [23]
bEffect sizes are for oral and pharyngeal cancers combined and were included in the meta-analysis for oral cancer only
cBased on parameter estimate and standard error reported in paper
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Fig. 2 Random effects model showing relative risk for mouth cancer for smokeless tobacco use
Siddiqi et al. BMC Medicine  (2015) 13:194 Page 15 of 22to Europe A and Americas A, respectively. For South-
East Asia B and D and Western Pacific B regions,
country-specific estimates from India were applied.
There were a few exceptions to this rule, because some
countries (UK, Mexico, Pakistan, China, Mongolia) dif-
fered in their SLT consumption patterns from their
respective regions (see Additional file 1: Appendix 4 for
details). In short, country-specific risk estimates for
cancers could only be fully applied to five regions. For
the remaining nine regions, our findings were imputed
either by applying statistically significant non-specific risk
estimates or none at all (Additional file 1: Appendix 4). Incase of ischaemic heart disease, Sweden was the only coun-
try with a pooled country-specific relative risk (0.98, 95 %
CI 0.90–1.07) obtained from a good number (more than
three) of studies. For 11 out of 14 regions, we used a large
multi-country study (INTERHEART)—conducted in 52
countries—to apply and deduce risk estimates. The three
regions (Europe A and C and Americas D) were excluded,
as these were not among those regions included in the
INTERHEART study (Additional file 1: Appendix 4). There
was one exception (UK) where INTERHEART study esti-
mates were applied because SLT products consumed in
the UK commonly originate from South Asia.
Fig. 3 Random effects model showing relative risk for pharyngeal cancer for smokeless tobacco use
Siddiqi et al. BMC Medicine  (2015) 13:194 Page 16 of 22Attributable burden
The attributable burden of SLT use is outlined in Table 4.
Our estimates indicate that in 2010, SLT use led to
1,711,539 DALYs lost and 62,283 deaths due to cancers
of mouth, pharynx, and oesophagus, and, based on data
from the benchmark 52 country INTERHEART study,
4,725,381 DALYs lost and 204,309 deaths from ischae-
mic heart disease. In total, SLT use caused the loss of
6,436,920 DALYs and 266,592 deaths. The figures show
that three-quarters of these deaths and loss of DALYs
were among males. This disease burden was found to be
distributed across all WHO sub-regions. However, nearly
85 % of the total burden attributable to SLT use was in
South-East Asia, with India alone accounting for 74 % of
the global burden, followed by Bangladesh (5 %).
Discussion
We have found that SLT is consumed worldwide and
that its use results in substantial, potentially avoidable,
morbidity and mortality. However, owing to marked dif-
ferences in the types of products available, patterns of
consumption, and associated risks, there are substantial
differences in the attributable burden between regions
and countries. In particular, SLT consumption in South-
East Asia leads to a much greater burden of disease than
in Sweden, despite its use being equally prevalent. This
is due to the much lower levels of TSNA and pH in SLT
products in Sweden compared to those found in SLT in
South-East Asia [6]. Similarly, SLT products used in theUSA have lower risk estimates than for those used in
South-East Asia.
We found that more than six million DALYs were lost
and over a quarter of a million deaths occurred in 2010
owing to SLT consumption. However, our estimates
require cautious interpretation because of a number of
potential limitations.
First, our analysis was limited to those countries and
diseases for which reliable prevalence and risk data were
available, respectively. Most global tobacco surveys that
reported on SLT consumption did not include all coun-
tries in the world. While global figures on smoking
prevalence were available, we did not find any SLT
prevalence figures for almost half of all countries. Where
SLT prevalence figures were available, two countries
(Micronesia and Saint Kitts & Nevis) were excluded
from the final estimates owing to an absence of data for
cancers in the 2010 Global Burden of Disease study.
Moreover, for certain disease outcomes, e.g. adverse
reproductive and oral health effects, poor quality as
well as limited quantity of evidence precluded their
inclusion.
Second, lack of country-specific risk estimates leads to
considerable uncertainty. Despite several countries
reporting SLT consumption, most did not have any reli-
able information on the types of SLT products used and
on their associated health risks. For example, studies
from several African countries reported high SLT con-
sumption (Table 2), but provided little information on
their hazard profile. There is some evidence, mainly
Fig. 4 Random effects model showing relative risk for oesophageal cancer for smokeless tobacco use
Siddiqi et al. BMC Medicine  (2015) 13:194 Page 17 of 22from Sudan [30], that products used in Africa tend to
have a higher pH than those used in Europe or in the
USA. However, we did not find any data on the risks as-
sociated with widespread SLT use in southern parts of
Africa. Likewise, various forms of SLT have been used in
parts of South America (Brazilian rapê or Venezuelan
chimó) for many years, yet there are no studies on the
health effects of such products. In the absence of
country-specific risk estimates, we assumed that in gen-
eral those populations that consume similar SLT prod-
ucts are likely to share similar health risks and
susceptibilities. We extrapolated and applied risk esti-
mates to most countries included in our analysis on thatbasis (Additional file 1: Appendix 4). For cancer, our ex-
trapolation was based on estimates obtained from sev-
eral studies; for ischaemic heart diseases, extrapolations
were mostly based on a single although large multi-
country study (INTERHEART). As a result, almost
three-quarters of the estimated SLT disease burden,
which is attributed to ischaemic heart disease, is uncer-
tain. Therefore, a cautious interpretation would be to ex-
clude ischaemic heart disease burden figures from our
estimates. However, in estimating these figures we had
already excluded those regions and their respective
countries that were not included in INTERHEART
study. As a pointer on future research, our study
Fig. 5 Random effects model showing relative risk for ischaemic heart disease for smokeless tobacco use
Siddiqi et al. BMC Medicine  (2015) 13:194 Page 18 of 22highlights the need to study risk of SLT consumption on
ischaemic heart diseases across the spectrum of SLT
products and consumption behaviours. In time, this will
produce more country-specific risk estimates, which
would undoubtedly improve the reliability of our esti-
mates presented here.
Third, the disease burden observed in 2010 is unlikely
to be a consequence of SLT consumption in recent years.
Therefore, our prevalence figures, obtained in surveys
carried out in the last decade and used in the estimates,
could be problematic. However, we assumed that the
SLT consumption rates have remained stable over the
last 30–40 years in these countries. We consider this as
a safe assumption given that SLT use is not a new trend
and historically embedded in culture and tradition in
many countries, most remarkably in South Asia [31].
Consumption trends based on repeated youth surveys inIndia and Bangladesh suggest that SLT use has remained
stable over the last decade [32]. Evidence from Sweden
suggests that while more people are using snus now than
25 years ago, the consumption trends, compared to
cigarette use, have essentially remained stable in this
period [33, 34].
Finally, the age range of the adult sampling frames
used in different SLT prevalence surveys varied, which
could also increase uncertainty. The main difference be-
tween two of the key categories used was in the adult
range starting from either ≥15 years or ≥25 years. Given
that the risk of cancers and ischemic heart disease accu-
mulates after many years of use well beyond young adult
age, it may not have made much of a difference to our
burden of disease estimates.
For the seven countries in South-East Asia region D,
we estimated that 55,060 deaths caused by cancers of
Table 4 Number of DALYs lost and deaths from SLT use in 2010, by WHO sub-region as defined in Additional file 1: Appendix 1
WHO sub-regionsa Mouth cancer Pharyngeal cancer Oesophageal cancer Ischaemic heart disease All causes
M F All M F All M F All M F All M F All
DEATHS
Africa D 86 36 123 15 2 17 157 77 233 2323 751 3074 2581 866 3448
Africa E 155 85 240 19 12 31 389 252 641 1202 923 2125 1765 1272 3037
Americas A 0 0 0 0 0 0 0 0 0 10,240 649 10,889 10,240 649 10,889
Americas B 90 11 102 28 3 31 74 9 83 1030 291 1321 1222 314 1536
Americas D 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Eastern Mediterranean B 11 1 12 1 0 2 4 1 5 441 74 515 457 76 534
Eastern Mediterranean D 933 254 1187 604 59 663 1012 129 1141 7401 926 8327 9950 1368 11,318
Europe A 66 13 78 16 2 18 244 38 282 539 145 684 865 197 1062
Europe B 146 3 148 57 1 58 260 2 262 5506 156 5662 5969 162 6130
Europe C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
South-East Asia B 438 396 835 129 58 187 243 139 382 3205 1852 5057 4016 2445 6461
South-East Asia D 11,527 6459 17,987 12,715 3485 16,200 15,247 5625 20,873 117,523 45,047 162,570 157,013 60,617 217,630
Western Pacific A 0 0 0 0 0 0 0 0 0 69 36 104 69 36 104
Western Pacific B 134 159 293 22 34 56 51 63 114 3167 814 3981 3374 1070 4443
Worldwide 13,586 7418 21,003 13,608 3656 17,264 17,680 6336 24,016 152,647 51,662 204,309 197,520 69,072 266,592
DALYs
Africa D 2516 1046 3562 452 65 517 4119 1906 6024 64,043 19,116 83,159 71,130 22,132 93,262
Africa E 4926 2293 7220 573 349 922 10,159 6290 16,449 33,502 21,109 54,610 49,159 30,042 79,201
Americas A 0 0 0 0 0 0 0 0 0 172,206 7213 179,419 172,206 7213 179,419
Americas B 2311 230 2541 734 63 797 1717 176 1893 22,252 4728 26,980 27,014 5197 32,210
Americas D 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Eastern Mediterranean B 285 36 321 33 9 43 86 20 106 9841 1383 11,224 10,246 1448 11,694
Eastern Mediterranean D 29,240 7669 36,909 16,446 1800 18,247 27,777 3613 31,390 187,394 21,544 208,938 260,857 34,627 295,483
Europe A 1514 224 1738 369 45 414 4949 545 5494 8397 1491 9888 15,230 2304 17,534
Europe B 4439 60 4499 1704 20 1724 6460 56 6517 115,640 1991 117,631 128,243 2128 130,371
Europe C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
South-East Asia B 10,968 7741 18,709 3217 1487 4704 5608 2983 8591 66,969 29,913 96,881 86,762 42,124 128,886
South-East Asia D 351,752 179,051 530,803 338,976 107,041 446,017 400,770 143,146 543,916 290,6993 938,528 3,845,521 3,998,491 1,367,766 5,366,257
Western Pacific A 0 0 0 0 0 0 0 0 0 1024 340 1364 1024 340 1364
Western Pacific B 3700 3567 7267 615 794 1409 1313 1485 2797 72,936 16,830 89,766 78,564 22,675 101,239
Worldwide 411,652 201,918 613,569 363,120 111,673 474,793 462,957 160,219 623,177 3,661,195 1,064,186 4,725,381 4,898,924 1,537,996 6,436,920
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SLT in 2010. This is a little higher than the estimates
from a recent study in which 50,000 deaths were attributed
to SLT in eight South Asian countries [4]. This discrepancy
may be explained by the fact that we used the most recent,
updated prevalence and burden of disease figures.
Our estimate does not include economic impact.
However, given the nature of the associated diseases,
it is likely that the SLT use imposes a huge economic
burden on weak health systems and poor economies.
Moreover, owing to higher consumption of SLT
among people of lower socio-economic status and in-
equitable access to health care in low-income and
middle-income countries, its use is likely to contrib-
ute to driving disadvantaged sections of these soci-
eties into further poverty. A disproportionate impact
on the male population (more than 70 % of disease
burden due to SLT is in males) is also likely to have
a disproportionate economic impact on societies in
terms of reduced workforce contributions by men.
On the other hand, effective legislation, policy, and
preventive programmes could avert this burden due
to SLT.
The signatories of the WHO’s Framework Convention
on Tobacco Control should, in addition to the focus on
reducing smoking consumption and related harm, now
also consider the need to regulate production, market-
ing, and labelling of SLT products. This is particularly
necessary in those countries where prevalence is high
and SLT products are manufactured at a large scale
without any checks on the carcinogenic level of their in-
gredients [35]. In countries where its use is largely lim-
ited to immigrant populations (such as in the UK) [36],
strict regulation and taxation policies should be enforced
which prevent import of SLT products and sale by local
shops.
SLT is an important health issue, applying to a large
part of the world. The data presented here are the most
comprehensive gathered and brought together thus far.
However, considerable uncertainties remain pertaining
to risk estimation of different diseases associated with
SLT use. Therefore more research is needed to investi-
gate the newly established and previously known adverse
health outcomes pertaining to SLT, particularly within
countries where prevalence is high but no research evi-
dence of risk estimation is available. Moreover, more de-
scriptive questions about the type of SLT products and
the pattern of use should be introduced into national
surveys and publications of such findings encompassing
all the regions.
Conclusions
Our study, a first attempt to assess global burden of dis-
ease due to SLT, estimates that more than six millionDALYs are lost and over a quarter of a million deaths
occur each year owing to its consumption. There is a
need to build on the insights obtained from efforts to re-
duce cigarette smoking-related harm and to investigate
strategies to reduce use of SLT and decrease the substan-
tial associated burden of harm.
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